Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX
Walleye Capital LLC has invested $2.44 million in REGENXBIO Inc. by acquiring 203,726 shares during the second quarter, making them one of many institutional investors in the company. REGENXBIO exceeded analyst expectations with its recent earnings report, posting $0.43 EPS and $108.02 million in revenue. Despite some recent analyst downgrades and price target reductions, the stock generally maintains a "Moderate Buy" rating with a consensus price target of $23.73.
REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research
Zacks Research has upgraded REGENXBIO (NASDAQ:RGNX) from a "strong sell" to a "hold" rating. This upgrade comes as the biotechnology company exceeded revenue and EPS estimates in its latest quarterly report, though it remains unprofitable. Institutional investors hold a significant portion of the company's shares, with BlackRock Inc. recently acquiring a new stake.
Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX
Assenagon Asset Management S.A. significantly reduced its stake in REGENXBIO Inc. by 82.7% in the second quarter, now holding 169,279 shares valued at $2.03 million. Despite this, institutional investors still own a substantial 88.08% of the company. REGENXBIO recently surpassed analyst estimates for quarterly revenue and earnings, though it remains unprofitable with a negative net margin.
(RGNX) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting mixed sentiment and a mid-channel oscillation pattern. It outlines institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. The analysis also includes a multi-timeframe signal breakdown for near-term, mid-term, and long-term horizons, suggesting choppy conditions for the stock.
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) for alleged federal securities law violations. The lawsuit claims that REGENXBIO made materially false and misleading statements regarding the development and commercialization of RGX‑111 for severe MPS I. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, are encouraged to join the lawsuit and have until April 14, 2026, to seek lead plaintiff status.
H.C. Wainwright lowers Regenxbio stock price target on equity offering
H.C. Wainwright has lowered its price target for Regenxbio (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's public offering of common stock in July 2026. This adjustment comes as Regenxbio reported Q2 2026 revenue of $108 million, including a significant milestone payment from AbbVie, and plans to submit a Biologics License Application for RGX-202 in Duchenne muscular dystrophy. Despite a recent downgrade by Barclays to Equalweight, the company's financial position has improved, extending its runway into Q4 2027.
H.C. Wainwright lowers Regenxbio stock price target on equity offering
H.C. Wainwright has lowered its price target for Regenxbio Inc. (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's public offering of common stock in July 2026. Despite the revised target, Regenxbio reported strong second-quarter 2026 results, including $108.0 million in revenue and $22.7 million in net income, bolstered by a significant milestone payment from AbbVie. The biotech firm is also progressing with its Biologics License Application for RGX-202 in Duchenne muscular dystrophy, aiming for accelerated approval in the second half of 2027.
H.C. Wainwright lowers Regenxbio stock price target on equity offering By Investing.com
H.C. Wainwright has reduced its price target for Regenxbio Inc. (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's July 2026 public stock offering. Regenxbio reported strong second-quarter 2026 revenues and net income, including a significant milestone payment from AbbVie. The company is also progressing with its Biologics License Application for RGX-202 in Duchenne muscular dystrophy, targeting potential accelerated approval in late 2027, despite a recent downgrade from Barclays due to regulatory uncertainty.
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of REGENXBIO Inc. to Contact the Firm Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO made materially false and misleading statements regarding the development and commercialization of its gene therapy, RGX‑111, for severe Mucopolysaccharidosis Type I. Investors who suffered losses are encouraged to contact the firm to discuss potentially becoming a lead plaintiff by April 14, 2026.
REGENXBIO (RGNX) Stock Drops Despite Profit Surprise And Longer Cash Runway
REGENXBIO (RGNX) experienced a nearly 5% stock drop despite reporting a surprise profit of US$0.43 EPS and US$108 million in revenue for Q2 2026, swinging from a significant loss. The company also extended its cash runway into Q4 2027 due to funding from AbbVie and an equity raise, supporting the advancement of its gene therapy programs. However, investors remain cautious due to the company's reliance on milestone-driven revenue, past treatment-related adverse events, and ongoing dilution concerns.
REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% Upside
Analysts have raised REGENXBIO Inc.'s average 12-month price target from $26 to $26.17, indicating a potential upside of approximately 149% from its August 5 closing price. The consensus rating for RGNX remains a "Buy" among 12 analysts, with 11 recommending a Buy and 1 a Hold.
Barclays downgrades Regenxbio stock rating on regulatory uncertainty
Barclays downgraded Regenxbio Inc. (NASDAQ:RGNX) to Equalweight from Overweight, setting a price target of $12.00 due to regulatory uncertainty surrounding its Duchenne muscular dystrophy (DMD) program and competitive landscape for wet age-related macular degeneration (wet AMD). Despite a recent 16% stock increase, the firm noted limited visibility on FDA's stance on DMD gene therapy, while positive data for wet AMD could provide upside. InvestingPro analysis suggests the stock is slightly overvalued and faces profitability challenges.
Barclays downgrades Regenxbio stock rating on regulatory concerns
Barclays has downgraded Regenxbio Inc. (NASDAQ:RGNX) to Equalweight from Overweight, citing regulatory concerns regarding its DMD gene therapy and the competitive landscape for its wAMD treatment. Despite a reduced price target of $12.00, Barclays noted potential upside from positive regulatory updates for DMD and successful wAMD data. The company recently reported Q2 2026 earnings exceeding profit expectations and bolstered its financial runway with a $100 million milestone payment and follow-on offering.
Barclays downgrades Regenxbio stock rating on regulatory uncertainty By Investing.com
Barclays downgraded Regenxbio Inc. (NASDAQ:RGNX) from Overweight to Equalweight with a price target of $12.00, citing regulatory uncertainty around its Duchenne muscular dystrophy (DMD) gene therapy program and the competitive landscape for its wet age-related macular degeneration program. Despite the stock's recent 16% rise, Barclays believes the current share price at around $11 appropriately reflects these concerns. InvestingPro analysis suggests the stock is slightly overvalued and faces profitability challenges, although the company recently surpassed profit expectations for Q2 2026 due to a milestone payment from AbbVie.
Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket
REGENXBIO reported Q2 2026 adjusted EPS of $0.43, significantly beating the $0.25 forecast, though revenue of $108.02 million missed estimates. Shares rose premarket due to a strengthened balance sheet, with pro forma cash exceeding $310 million after a $100 million AbbVie milestone and a follow-on offering, extending their cash runway into Q4 2027. The company highlighted progress in its gene-therapy pipeline, including key milestones for Duchenne muscular dystrophy and retinal disease programs.
REGENXBIO (Nasdaq: RGNX) turns Q2 profit on $100M AbbVie milestone
REGENXBIO (Nasdaq: RGNX) reported a significant turnaround in Q2 2026, posting a net income of $22.7 million ($0.43 per share) compared to a $70.9 million net loss in Q2 2025. This profit was largely driven by $108.0 million in total revenues, primarily from a $100.0 million milestone payment from AbbVie related to the NAAVIGATE diabetic retinopathy study. The company also highlighted strong pipeline progress, including a planned BLA submission for RGX-202 for Duchenne muscular dystrophy in Q3 2026 and positive long-term data for surabgene lomparvovec (ABBV-RGX-314) in wet AMD and diabetic retinopathy.
Form 8K Regenxbio Inc For: 6 August By Investing.com
This article announces the filing of a Form 8K by Regenxbio Inc. on August 6th. The content of the Form 8K itself is not detailed, but the article contextualizes it within broader financial market news and data provided by Investing.com.
REGENXBIO reports Q2 2026: $108.0M revenue, $22.7M net income, cash pro forma >$310M
REGENXBIO announced strong financial results for Q2 2026, with revenues reaching $108.0 million and net income at $22.7 million. The company's cash position, including July 2026 milestone and offering proceeds, stands at over $313 million pro forma. Key upcoming catalysts include a BLA initiation for RGX-202 in Q3 2026 and pivotal wet AMD topline data expected in Q4 2026.
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO Inc. reported its second quarter 2026 financial results, highlighting strong clinical execution and a solid cash runway. Key achievements include the AFFINITY DUCHENNE® trial meeting its primary endpoint, the initiation of the NAAVIGATE study for diabetic retinopathy, and FDA reaffirming the path forward for RGX-121 for Hunter syndrome. The company also secured over $200 million in new capital, extending its cash runway into Q4 2027.
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and certain officers, alleging federal securities law violations. The lawsuit claims that REGENXBIO made false and misleading statements about the development and commercialization of its gene therapy RGX‑111, overstating its efficacy and safety. Shareholders who suffered losses between February 9, 2022, and January 27, 2026, are encouraged to join the lawsuit and have until April 14, 2026, to request to be appointed as lead plaintiff.
RGNX Looks 33.1% Undervalued on GF Value™ Despite Possible Value Trap
Regenxbio Inc (RGNX) is set to report its Q2 earnings, with analysts forecasting a significant year-over-year revenue increase despite caution reflected in recent estimate revisions. While GuruFocus's GF Value™ suggests RGNX is 33.1% undervalued, its GF Score™ of 60 highlights weak financial strength and profitability due to ongoing losses and high debt. Investors are advised to consider the mixed signals from insider selling and cautious institutional sentiment alongside potential revenue growth.
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) and its officers. The lawsuit alleges that REGENXBIO made false and misleading statements regarding its gene therapy RGX-111, for which investors who purchased securities between February 9, 2022, and January 27, 2026, have an opportunity to lead the class action. Investors have until April 14, 2026, to request to be appointed as lead plaintiff.
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and certain officers, alleging violations of federal securities laws. The lawsuit claims that REGENXBIO made misleading statements regarding its RGX-111 gene therapy, overstating its efficacy and safety during the Class Period from February 9, 2022, to January 27, 2026. Investors with substantial losses are encouraged to join the lawsuit, with a deadline to request lead plaintiff status by April 14, 2026.
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and certain officers. The lawsuit seeks damages for alleged violations
Regenxbio Inc expected to post earnings of 6 cents a share - Earnings Preview
Regenxbio Inc. (RGNX) is projected to report earnings of 6 cents per share. This financial forecast is provided as an earnings preview by Refinitiv. The full article is available to TradingView subscribers, offering unlimited access to news sources.
Earnings Preview: Regenxbio to Report Financial Results Pre-market on August 06
This article announces that Regenxbio Inc. (RGNX) is scheduled to release its financial results pre-market on August 6. Analysts are expecting a consensus loss per share of -$0.98. The report will likely detail the company's performance and provide insights into its gene therapy programs.
REGENXBIO's second-quarter financial update is set for Aug. 6
REGENXBIO (Nasdaq: RGNX) will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and provide operational highlights. Investors and analysts can register for the webcast, with a replay available approximately two hours after the call. The company specializes in AAV gene therapy, advancing treatments for rare and retinal diseases.
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) announced it will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its second quarter 2026 financial results and operational highlights. The biotechnology company, known for its AAV gene therapy developments for rare and retinal diseases, will provide a webcast and a replay for interested listeners and analysts.
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) announced it will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss its financial results for the second quarter ended June 30, 2026, and operational highlights. The biotechnology company, focused on AAV gene therapy, is advancing treatments for rare and retinal diseases. A webcast and replay will be available for listeners and analysts.
(RGNX) Risk Channels and Responsive Allocation
This article provides a detailed analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting weak sentiment across all time horizons which supports a short bias. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes a significant 122.3:1 risk-reward setup targeting a 38.8% gain versus 0.3% risk.
RGNX|Regenxbio Inc|Price:10.180|Chg%:+0.060
The article provides a comprehensive stock analysis of Regenxbio Inc (RGNX) from TradingKey, highlighting its relatively weak fundamentals but significant growth potential. The stock is considered fairly valued, with high institutional ownership and multiple "Buy" ratings from analysts. The company, a clinical-stage biotechnology firm, focuses on gene therapy programs for retinal, neuromuscular, and neurodegenerative diseases.
Total common shares outstanding of REGENXBIO, Inc. – HAM:RB0
This article provides financial information for REGENXBIO, Inc. (HAM:RB0) listed on the Hamburg Stock Exchange, specifically focusing on its total common shares outstanding. It indicates that the market was closed with no trades recorded at the time of publication. The data is made available by various financial service providers including ICE Data Services and FactSet.
Diluted shares outstanding of REGENXBIO, Inc. – HAM:RB0
The article provides a financial snapshot of REGENXBIO, Inc. (HAM:RB0) on TradingView, specifically focusing on its diluted shares outstanding. It notes that the market for HAM:RB0 is currently closed with no trades recorded. The content seems to be a financial data placeholder, indicating where specific values and changes related to diluted shares outstanding would be displayed.
Regenxbio Inc (RGNX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Regenxbio Inc's (RGNX) dividend and stock split history, indicating that no dividends have been distributed over the past five years. It presents current stock performance data, including its market cap and recent price change. The page is part of a financial tracking platform, TradingKey, which offers company financials and analysis.
Inventory turnover of REGENXBIO, Inc. – HAM:RB0
This article focuses on the inventory turnover of REGENXBIO, Inc. (HAM:RB0). It appears to be a financial data page from TradingView, indicating that the market is closed and no trades have occurred. The content suggests the financial data provided is made by humans and offers various resources for market analysis.
Regenxbio Inc (RGNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Regenxbio Inc (RGNX), detailing its price momentum score, current trading range, and a summary of technical indicators and moving averages. RGNX currently has a price momentum score of 5.89 and is trading between a resistance level of 14.27 and a support level of 6.81, suitable for range-bound swing trading. The technical indicators show a mix of neutral, sell, and oversold signals, while moving averages present both buy and sell signals, leading to an overall Neutral signal today based on technical analysis.
REGENXBIO Inc. Revenue Breakdown – NASDAQ:RGNX
The article provides a revenue breakdown for REGENXBIO Inc. (NASDAQ: RGNX), highlighting that the company generated $170.44 million USD last year. Its top-performing segment was Gene Therapies, contributing the entire $170.44 million, an increase from $83.33 million the previous year. Japan was the largest regional contributor, accounting for $74.99 million in revenue.
REGENXBIO Inc. (RGNX) stock price, news, quote and history
This article provides comprehensive financial data for REGENXBIO Inc. (RGNX), including its stock price, historical performance, earnings, and analyst insights. As of July 24, 2026, RGNX closed at $9.73, down 5.07%, with an after-hours price of $9.79. The company, a clinical-stage biotechnology firm, specializes in gene therapies and has several product candidates in its pipeline.
Lawsuit alleges Regenxbio misled investors on gene therapy trial results for Hurler Syndrome.
Kuehn Law is investigating Regenxbio, Inc. over allegations of providing false or misleading information regarding the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based on Phase I/II study data. Shareholders who bought Regenxbio stock before February 9, 2022, are encouraged to contact the law firm to assert their rights, bringing concerns about transparency in biotech reporting to light.
Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. This investigation stems from a federal securities lawsuit alleging that Regenxbio provided false information regarding its RGX-111 trial study, specifically concerning its efficacy and safety. The law firm is encouraging investors who purchased RGNX prior to February 9, 2022, to contact them.
Frontier tech research, news & data
This article reports on an 8-K filing by REGENXBIO Inc. on July 20, 2026, detailing other events. It also highlights a research report on fuel-cell deployments at U.S. data centers, indicating 154 MW of operating capacity and 6.31 GW in proposed projects across various states.
Regenxbio's Gene Therapy Shows 5-Year Vision Gains in AMD
Regenxbio reported five-year durability for its gene therapy, surabgene lomparvovec (sura-vec), showing stable to improved vision in patients with wet AMD after a single subretinal dose. These long-term results come ahead of pivotal Phase III data in Q4 2026, which will compare sura-vec against existing treatments. The company also shared promising 2.5-year data for sura-vec administered via suprachoroidal injection in diabetic retinopathy.
REGENXBIO (NASDAQ: RGNX) prices stock and warrant sale, netting $107.8M
REGENXBIO Inc. has priced an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, expecting to net approximately $107.8 million after expenses, including the full exercise of the underwriters' 30-day option for additional shares. The offering is anticipated to close on July 20, 2026, subject to customary conditions. The pre-funded warrants have a nominal exercise price of $0.0001 per share, are exercisable at any time, and do not expire.
Regenxbio prices expected $100M public offering
US biotech Regenxbio (Nasdaq: RGNX) announced the pricing of an underwritten public offering expected to raise around $100.0 million. The offering includes common stock at $9.00 per share and pre-funded warrants at $8.9999 per warrant. Following the announcement, the company's shares closed down 11.7% at $9.89.
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
REGENXBIO Inc. announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet Age-related Macular Degeneration (AMD) and diabetic retinopathy (DR). The data, presented at the ASRS Annual Meeting, showed durable efficacy and safety through five years for wet AMD patients and 2.5 years for diabetic retinopathy patients, reinforcing its potential as a one-time treatment to reduce the burden of frequent injections. Topline data for pivotal wet AMD studies are expected in Q4 2026.
Five-Year Wet AMD Follow-Up Reports Stable-to-Improved Vision
REGENXBIO announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) at the ASRS 2026 meeting. Five-year data for wet AMD showed stable to improved visual acuity and reduced anti-VEGF injection burden, with no new safety signals. For DR, 2.5-year data demonstrated significant improvement in DRSS and prevention of vision-threatening events without intraocular inflammation.
REGENXBIO Stock Slides After $100M Equity Offering Pricing
REGENXBIO Inc. (RGNX) stock dropped over 11% after pricing a $100 million equity and pre-funded warrant offering at $9.00 per share. This offering, intended to fund its late-stage gene therapy pipeline, has raised concerns about dilution and near-term selling pressure. The company faces ongoing financial weakness, deeply negative profitability, and legal issues concerning RGX-111 disclosures, leading to a negative analyst sentiment and a shifted technical outlook to corrective.
REGENXBIO Stock Slides After $100M Equity Offering Shock
REGENXBIO Inc. (RGNX) stock dropped by 11.92% after announcing a $100 million public offering of common stock and pre-funded warrants at $9.00 per share to fund operations and pipeline development. This equity raise, coupled with a shareholder litigation firm investigating alleged misleading statements about RGX-111’s efficacy, led to significant dilution and heightened volatility. The company, which is in heavy build mode with deeply negative operating margins, aims to bolster its balance sheet despite the immediate negative market reaction and increased risk profile.
REGENXBIO (NASDAQ: RGNX) launches $100M equity and pre-funded warrant raise
REGENXBIO Inc. (NASDAQ: RGNX) is conducting a primary offering of 10,003,889 shares of common stock and 1,111,111 pre-funded warrants for a total public offering price of $100 million. The public offering price is $9.00 per share and $8.9999 per warrant, with underwriters having a 30-day option to purchase an additional 1,667,250 shares. Net proceeds are estimated at $93.7 million, intended for general corporate purposes including clinical trials and pipeline development, particularly for RGX-202 for Duchenne muscular dystrophy.
Regenxbio (RGNX) Launches $100 Million Public Offering
Regenxbio Inc. (RGNX) announced a public offering of common stock and pre-funded warrants aimed at raising approximately $100 million to support its gene therapy research and development. The company, which has a market cap of $579.01 million, has a GF Score of 60, indicating moderate potential for long-term returns despite challenges in financial strength and profitability. Notably, insiders have sold $0.9 million in stock over the past three months, raising concerns about short-term prospects.
